BC Week In Review | May 25, 2018
Financial News

Rain raises $18M to advance tarloxotinib in NSCLC

Rain Therapeutics Inc. (Fremont, Calif.) closed on May 21 a tranched $18.4 million series A round led by Biotechnology Venture Fund (BVF), with participation from fellow new investors Perceptive Advisors, Auckland UniServices' Inventors Fund and...
BC Extra | May 21, 2018
Financial News

Rain raises $18M to advance tarloxotinib in NSCLC

Rain Therapeutics Inc. (Fremont, Calif.) closed a tranched $18.4 million series A round led by Biotechnology Venture Fund (BVF), with participation from fellow new investors Perceptive Advisors, Auckland UniServices' Inventors Fund and FMB Research’s Franklin...
BC Innovations | May 9, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Leishmaniasis; tuberculosis; trypanosome Cell culture, hamster and mouse studies identified nitroimidazooxazine-based compounds that could help treat visceral leishmaniasis (VL), tuberculosis (TB) or Chagas disease. Chemical synthesis and testing of nitroimidazooxazine analogs in in vitro...
BC Week In Review | Mar 30, 2017
Financial News

Upside Biotechnologies completes venture financing

On March 21, regenerative medicine company Upside Biotechnologies Ltd. (Auckland, New Zealand) raised NZ$2.3 million ($1.6 million) in a series A round with ICE Angels, Tuhua Ventures, the University of Auckland Investors Fund, Cure Kids...
BC Week In Review | Nov 18, 2016
Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat NSCLC and squamous cell carcinoma of the head and neck (SCCHN) or skin...
BC Week In Review | Nov 18, 2016
Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and...
BioCentury | Mar 7, 2016
Product Development

Getting hip in osteoporosis

Investors were quick to conclude that Amgen Inc. and UCB Group's romosozumab may be at a disadvantage in the osteoporosis market after the partners reported a miss on non-vertebral fracture rates, and an apparently lower...
BC Week In Review | Jan 4, 2016
Company News

Threshold cancer news

Threshold will reduce headcount by about 66% to 20-25 to focus resources on two ongoing Phase II trials of tarloxotinib ( TH-4000 ) to treat non-small cell lung cancer (NSCLC) and squamous cell carcinomas of the head...
BC Week In Review | Sep 14, 2015
Clinical News

Tarloxotinib: Phase II started

Threshold began an open-label, U.S. and Australian Phase II trial to evaluate 150 mg/m 2 IV tarloxotinib on days 1, 8, 15 and 22 of a 28-day cycle in up to 68 patients. Threshold has...
BC Week In Review | May 25, 2015
Company News

Cancer Research UK, Medivir deal

Cancer Research UK’s Cancer Research Technology (CRT) Ltd. commercialization and development arm partnered with Medivir to develop small molecules that target cell surface protein ADAM metallopeptidase domain 8 (ADAM8) . Under the two-year deal, Medivir will...
Items per page:
1 - 10 of 34
BC Week In Review | May 25, 2018
Financial News

Rain raises $18M to advance tarloxotinib in NSCLC

Rain Therapeutics Inc. (Fremont, Calif.) closed on May 21 a tranched $18.4 million series A round led by Biotechnology Venture Fund (BVF), with participation from fellow new investors Perceptive Advisors, Auckland UniServices' Inventors Fund and...
BC Extra | May 21, 2018
Financial News

Rain raises $18M to advance tarloxotinib in NSCLC

Rain Therapeutics Inc. (Fremont, Calif.) closed a tranched $18.4 million series A round led by Biotechnology Venture Fund (BVF), with participation from fellow new investors Perceptive Advisors, Auckland UniServices' Inventors Fund and FMB Research’s Franklin...
BC Innovations | May 9, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Leishmaniasis; tuberculosis; trypanosome Cell culture, hamster and mouse studies identified nitroimidazooxazine-based compounds that could help treat visceral leishmaniasis (VL), tuberculosis (TB) or Chagas disease. Chemical synthesis and testing of nitroimidazooxazine analogs in in vitro...
BC Week In Review | Mar 30, 2017
Financial News

Upside Biotechnologies completes venture financing

On March 21, regenerative medicine company Upside Biotechnologies Ltd. (Auckland, New Zealand) raised NZ$2.3 million ($1.6 million) in a series A round with ICE Angels, Tuhua Ventures, the University of Auckland Investors Fund, Cure Kids...
BC Week In Review | Nov 18, 2016
Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat NSCLC and squamous cell carcinoma of the head and neck (SCCHN) or skin...
BC Week In Review | Nov 18, 2016
Clinical News

Tarloxotinib: Development discontinued

Threshold discontinued development of tarloxotinib after reporting interim data from the Phase II TH-CR-601 and TH-CR-602 trials of the compound to treat non-small cell lung cancer (NSCLC) and squamous cell carcinoma of the head and...
BioCentury | Mar 7, 2016
Product Development

Getting hip in osteoporosis

Investors were quick to conclude that Amgen Inc. and UCB Group's romosozumab may be at a disadvantage in the osteoporosis market after the partners reported a miss on non-vertebral fracture rates, and an apparently lower...
BC Week In Review | Jan 4, 2016
Company News

Threshold cancer news

Threshold will reduce headcount by about 66% to 20-25 to focus resources on two ongoing Phase II trials of tarloxotinib ( TH-4000 ) to treat non-small cell lung cancer (NSCLC) and squamous cell carcinomas of the head...
BC Week In Review | Sep 14, 2015
Clinical News

Tarloxotinib: Phase II started

Threshold began an open-label, U.S. and Australian Phase II trial to evaluate 150 mg/m 2 IV tarloxotinib on days 1, 8, 15 and 22 of a 28-day cycle in up to 68 patients. Threshold has...
BC Week In Review | May 25, 2015
Company News

Cancer Research UK, Medivir deal

Cancer Research UK’s Cancer Research Technology (CRT) Ltd. commercialization and development arm partnered with Medivir to develop small molecules that target cell surface protein ADAM metallopeptidase domain 8 (ADAM8) . Under the two-year deal, Medivir will...
Items per page:
1 - 10 of 34